Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sage Therapeutics, Inc. - Common Stock (NQ: SAGE ) 5.540 -0.190 (-3.32%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sage Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Where Sage Therapeutics Stands With Analysts December 16, 2024 Via Benzinga Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference November 26, 2024 From Sage Therapeutics, Inc. Via Business Wire This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday November 21, 2024 Via Benzinga After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder November 20, 2024 Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints. Via Benzinga Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics November 20, 2024 Via Benzinga Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease November 20, 2024 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics's Earnings: A Preview October 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session October 30, 2024 Via Benzinga Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates October 29, 2024 From Sage Therapeutics, Inc. Via Business Wire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) October 25, 2024 From The Law Offices of Frank R. Cruz Via Business Wire Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights October 23, 2024 From Rosen Law Firm Via Business Wire Faruqi & Faruqi Reminds Sage Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE October 23, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm October 22, 2024 From Bragar Eagel & Squire Via GlobeNewswire SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline October 21, 2024 From Bernstein Liebhard LLP Via GlobeNewswire After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce October 17, 2024 Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... Via Benzinga Topics Workforce Exposures Layoff Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio October 17, 2024 From Sage Therapeutics, Inc. Via Business Wire SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics October 16, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm October 15, 2024 From Bragar Eagel & Squire Via GlobeNewswire Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 October 15, 2024 From Sage Therapeutics, Inc. Via Business Wire SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline October 14, 2024 From Bernstein Liebhard LLP Via GlobeNewswire SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics October 11, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm October 09, 2024 From Bragar Eagel & Squire Via GlobeNewswire Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday October 09, 2024 Via Benzinga After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study October 08, 2024 Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 08, 2024 Via Benzinga Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease October 08, 2024 From Sage Therapeutics, Inc. Via Business Wire SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline October 07, 2024 From Bernstein Liebhard LLP Via GlobeNewswire ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE October 06, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm October 05, 2024 From Bragar Eagel & Squire Via GlobeNewswire SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline October 04, 2024 From Robbins LLP Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
